Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0851184 (
thinning
)
11,252
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Humans with heterozygous inactivating mutations of the Lis1 gene display type I lissencephaly, a severe form of cortical dysplasia hypothesized to result from abnormal neuronal migration. Previously we reported the construction of an allelic series of the Lis1 gene in mice to analyze the effects of graded reduction of
LIS1
protein on the pathogenesis of this disorder and demonstrated a cell autonomous defect in neuronal migration (Hirotsune et al., 1998). Here we report the systematic examination of the consequences of dosage reduction of
LIS1
on neocortical development using wild-type, null heterozygous (45%
LIS1
protein), and compound null/hypomorphic (35%
LIS1
protein) mice. The development of the preplate, Cajal-Retzius cells, and the radial glial scaffold appeared unaffected by
LIS1
levels. However, a dose-dependent morphologic change in disorganization of the subplate was noted.
LIS1
dose-dependent defects in neuronal migration were found in vivo and in vitro. The position and number of mitotic cells in the ventricular zone were more abnormal as
LIS1
levels decreased, suggesting defects in interkinetic nuclear migration and neuroblast proliferation.
LIS1
dose-dependent progressive
thinning
of the cortex and ventricular zone occurred by programmed cell death. Thus, in addition to its requirement for cell autonomous neuronal migration,
LIS1
influences the generation and survival of cortical ventricular zone neuroblasts. These studies reveal the importance of
LIS1
levels in orderly cerebral cortical morphogenesis and suggest new insights into the pathogenesis of type I lissencephaly.
...
PMID:Multiple dose-dependent effects of Lis1 on cerebral cortical development. 1262 76